论文部分内容阅读
从1981年1月至1991年12月，我们共收治可手术见期乳腺癌61例，其中术前化疗36例，非术前化疗25例。术前化疗组中，经尺动脉插管给药19例，静脉给药17例，有效率分别为73．7％和76．5％（P>0．05），5年生存率分别为68．4％和70．6％（P>0．05），总有效率和5年生率率分别为75．0％和69．4％。5年生存率明显高于非术前化疗组的36．0％（P<0．05）。结果表明：术前化疗对改善可手术Ⅲ期乳腺癌的预后有其重要的意义。
From January 1981 to December 1991, we treated a total of 61 patients with operable stage breast cancer, including 36 preoperative chemotherapy and 25 non-preoperative chemotherapy. In the preoperative chemotherapy group, 19 patients received catheterization through the ulnar artery and 17 received intravenous administration. The effective rates were 73.7% and 76.5%, respectively (P>0.05). The 5-year survival rate was 68. .4% and 70.6% (P>0.05), and the total effective rate and 5-year rate were 75.0% and 69.4%, respectively. The 5-year survival rate was significantly higher than that of the non-preoperative chemotherapy group (36.0%) (P < 0.05). The results showed that preoperative chemotherapy has important implications for improving the prognosis of operable stage III breast cancer.